Theravance's TD-4208 meets in Phase IIb COPD trial

Theravance Inc. (NASDAQ:THRX) said once-daily TD-4208 as a nebulized aqueous solution met the primary endpoint of improving trough forced expiratory volume in 1 second (FEV1) from baseline to day seven vs. placebo in the Phase IIb Study 0091 to treat chronic obstructive pulmonary disease (COPD). The double-blind, dose-ranging, crossover, New Zealand trial enrolled 62 patients with moderate to severe COPD. TD-4208 is an inhaled long-acting muscarinic antagonist (LAMA). Theravance, which announced the data after market close, was off $0.79 to $36.63 on Wednesday. ...